Two Companies Submit Competing Weight Loss Drugs to FDA

The weight loss market, led by Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, is evolving with potential new approvals on the horizon. Wegovy, containing semaglutide, mimics GLP-1 hormones to regulate insulin and satiety, while Novo Nordisk’s CagriSema, a dual agonist, targets both GLP-1 and amylin for enhanced effectiveness. This dual approach parallels Eli Lilly’s Zepbound, a dual GLP-1/GIP agonist. The competitive landscape continues to shift as these companies advance their innovative treatments.

Want More Context? 🔎